<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829123</url>
  </required_header>
  <id_info>
    <org_study_id>HEC88473-DM-102</org_study_id>
    <nct_id>NCT04829123</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongguan HEC Biopharmaceutical R&amp;D Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongguan HEC Biopharmaceutical R&amp;D Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, double blind, placebo controlled, single and multiple ascending dose, safety,&#xD;
      tolerability, pharmacokinetic, and pharmacodynamic study of HEC88473 in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first time HEC88473 will be administered to humans. The aim of this study is to&#xD;
      obtain safety, tolerability, PK, PD, and immunogenicity data of HEC88473 SC administration as&#xD;
      single and multiple ascending doses in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose of HEC88473</measure>
    <time_frame>Baseline to day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple dose of HEC88473</measure>
    <time_frame>Baseline to day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Predose and postdose 4, 8, 10, 12, 14, 24, 48, 72, 96, 168, 216, and 336 hours</time_frame>
    <description>Maximum observed plasma concentration of HEC88473</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Predose and postdose 4, 8, 10, 12, 14, 24, 48, 72, 96, 168, 216, and 336 hours</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OGTT</measure>
    <time_frame>Predose and postdose 2, 4 hours</time_frame>
    <description>Oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the incidence of anti drug antibodies (ADA) developed against HEC88473 after dosing</measure>
    <time_frame>Baseline to day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Single dose of 0.5 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 0.5 mg HEC88473 (N=6) or placebo(N=2) after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 1.7 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 1.7 mg HEC88473 (N=6) or placebo(N=2) after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 5.1 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 5.1 mg HEC88473 (N=6) or placebo(N=2) after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 10.2 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 10.2 mg HEC88473 (N=6) or placebo(N=2) after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 17.0 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 17.0 mg HEC88473 (N=6) or placebo(N=2) after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 25.5 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 25.5 mg HEC88473 (N=6) or placebo(N=2) after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 34.0 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 34.0 mg HEC88473 (N=6) or placebo(N=2) after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 44.2 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 44.2 mg HEC88473 (N=6) or placebo(N=2) after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses of 1.7 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a weekly dose of 1.7 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses of 5.1 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a weekly dose of 5.1 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses of 10.2 mg HEC88473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a weekly dose of 10.2 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC88473 injection</intervention_name>
    <description>HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen</description>
    <arm_group_label>Multiple doses of 1.7 mg HEC88473</arm_group_label>
    <arm_group_label>Multiple doses of 10.2 mg HEC88473</arm_group_label>
    <arm_group_label>Multiple doses of 5.1 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 0.5 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 1.7 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 10.2 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 17.0 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 25.5 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 34.0 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 44.2 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 5.1 mg HEC88473</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by subcutaneous injection in the abdomen</description>
    <arm_group_label>Multiple doses of 1.7 mg HEC88473</arm_group_label>
    <arm_group_label>Multiple doses of 10.2 mg HEC88473</arm_group_label>
    <arm_group_label>Multiple doses of 5.1 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 0.5 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 1.7 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 10.2 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 17.0 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 25.5 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 34.0 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 44.2 mg HEC88473</arm_group_label>
    <arm_group_label>Single dose of 5.1 mg HEC88473</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, of any race, between 18 and 60 years of age, inclusive, at&#xD;
             screening.&#xD;
&#xD;
          2. Body weight â‰¥ 50 kg, and body mass index between 18.0 and 40.0 kg/m2, inclusive, at&#xD;
             screening.&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12 lead ECG, vital signs measurements, and clinical laboratory&#xD;
             evaluations at screening as assessed by the investigator (or designee).&#xD;
&#xD;
          4. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the investigator (or designee).&#xD;
&#xD;
          2. History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the investigator (or designee).&#xD;
&#xD;
          3. History of alcoholism or drug/chemical abuse within 2 years prior to the first dosing.&#xD;
&#xD;
          4. Alcohol consumption of &gt; 21 units per week for males and &gt; 14 units per week for&#xD;
             females. One unit of alcohol equals 12 oz (360 mL) beer, 1Â½ oz (45 mL) liquor, or 5 oz&#xD;
             (150 mL) wine.&#xD;
&#xD;
          5. Positive alcohol breath test result or positive urine drug screen (confirmed by&#xD;
             repeat) at screening and/or check-in.&#xD;
&#xD;
          6. Immunization with a live attenuated vaccine or coronavirus vaccination within 1 month&#xD;
             prior to the first dosing or planned vaccination during the course of the study.&#xD;
&#xD;
          7. Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 30 days or 5 half-lives (if known), whichever is&#xD;
             longer, prior to the first dosing.&#xD;
&#xD;
          8. Use or intend to use any prescription medications/products other than hormone&#xD;
             replacement therapy, oral, implantable, transdermal, injectable, or intrauterine&#xD;
             contraceptives within 14 days prior to first dosing, unless deemed acceptable by the&#xD;
             investigator (or designee).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Lemech, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientia Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Lemech, Doctor</last_name>
    <phone>+61 2 93825807</phone>
    <email>charlotte.lemech@scientiaclinicalresearch.com.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scientia Clinical Research</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Lemech, Doctor</last_name>
      <phone>+61 2 93825807</phone>
      <email>charlotte.lemech@scientiaclinicalresearch.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

